{
  "parties": [
    "EKR",
    "PPI dated as of August 10"
  ],
  "effective_date": null,
  "governing_law": "California",
  "payment_terms": {
    "text": "payment terms. PPI has provided EKR: (i) all information regarding sales by Endo Pharmaceuticals during  the six month period prior to the Effective Date and (ii) all information regarding the number of units of Product and Endo Product that were  in the possession or control of PPI or Endo Pharmaceuticals (and their respective distributors or wholesalers) as of the Effective Date (the  \"Known In-Channel Product Units\"). Within 10 days of the end of each month following the Effective Date, PPI shall provide EKR with  copies of: (i) any reports provided by Endo Pharmaceuticals of the number of",
    "start": 28870,
    "end": 29470,
    "confidence": 0.72,
    "source": "regex"
  },
  "termination_clause": {
    "text": "termination or expiration of this Agreement, EKR shall promptly transfer the Domain Names back to PPI.   2.5 Condition of Appointment. The acceptance of forecasts and orders for the Products (as provided in the Supply Agreement), and PPI's obligation to supply the Product to EKR shall at all times be conditioned by the Marketing Authorization for the Product being in force in  the country of Territory to which such acceptance and order relates.\n\n3. Undertakings of PPI   3.1 Manufacturing Activities. Subject to Section 17.5, PPI shall manufacture and supply, or procure the manufacture and supply of, the Product  in accordance with the terms and conditions of the Supply Agreement.   3.2 Transfer of Transferred NDA. Effective as of the Agreement Date, PPI hereby sells, transfers, conveys and assigns to",
    "start": 17950,
    "end": 18761,
    "confidence": 0.72,
    "source": "regex"
  },
  "_doc_id": "PACIRA PHARMACEUTICALS, INC. - A_R STRATEGIC LICENSING, DISTRIBUTION AND MARKETING AGREEMENT.txt",
  "_char_count": 145168,
  "_provenance": {
    "governing_law": {
      "source": "spacy"
    }
  }
}